RIGEL PHARMACEUTICALS INC (RIGL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 150M 300M 450M Q1 '19: 57.1M Q2 '19: 65.8M Q3 '19: 81.7M Q4 '19: 59.3M Q1 '20: 102.4M Q2 '20: 108M Q3 '20: 105.6M Q4 '20: 108.6M Q1 '21: 133.9M Q2 '21: 144.1M Q3 '21: 147.3M Q4 '21: 149.2M Q1 '22: 85M Q2 '22: 88.5M Q3 '22: 89.4M Q4 '22: 120.2M Q1 '23: 129.6M Q2 '23: 126.6M Q3 '23: 132.4M Q4 '23: 116.9M Q1 '24: 120.3M Q2 '24: 130.3M Q3 '24: 157.5M Q4 '24: 179.3M Q1 '25: 203.1M Q2 '25: 267.9M Q3 '25: 282.1M Q4 '25: 294.3M Q1 '26: 299.8M Q2 '26: 276.8M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 25M 50M 75M Q1 '19: 21.6M Q2 '19: 29.7M Q3 '19: 36.3M Q4 '19: 42.9M Q1 '20: 47.4M Q2 '20: 52.3M Q3 '20: 57M Q4 '20: 60.8M Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20 Q4 '20

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '11: -86.4M Q1 '12: -88.8M Q2 '12: -92.1M Q3 '12: -99.7M Q4 '12: -99.4M Q1 '13: -101.8M Q2 '13: -99.8M Q3 '13: -98.1M Q4 '13: -89.5M Q1 '14: -86.1M Q2 '14: -88.7M Q3 '14: -85.8M Q4 '14: -91.2M Q1 '15: -87.1M Q2 '15: -75.6M Q3 '15: -61.4M Q4 '15: -51.7M Q1 '16: -51.1M Q2 '16: -50.7M Q3 '16: -66.7M Q4 '16: -69.7M Q1 '17: -68.4M Q2 '17: -74.1M Q3 '17: -69.2M Q4 '17: -79.6M Q1 '18: -88.1M Q2 '18: -94.9M Q3 '18: -101.4M Q4 '18: -72.7M Q1 '19: -66.3M Q2 '19: -61.6M Q3 '19: -49.2M Q4 '19: -69.1M Q1 '20: -29.7M Q2 '20: -25.7M Q3 '20: -27.5M Q4 '20: -29M Q1 '21: -8.2M Q2 '21: -3.9M Q3 '21: -9.9M Q4 '21: -12.5M Q1 '22: -80.5M Q2 '22: -80.4M Q3 '22: -79M Q4 '22: -55.5M Q1 '23: -42M Q2 '23: -34.3M Q3 '23: -20.4M Q4 '23: -20.5M Q1 '24: -14.7M Q2 '24: -9M Q3 '24: 9.5M Q4 '24: 24.2M Q1 '25: 43.9M Q2 '25: 104.6M Q3 '25: 119M Q4 '25: 125.5M Q1 '26: 124.6M Q2 '26: 87M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-150M 0 150M 300M 450M Q4 '11: -86M Q1 '12: -88.4M Q2 '12: -91.6M Q3 '12: -99.2M Q4 '12: -98.8M Q1 '13: -101.2M Q2 '13: -99.3M Q3 '13: -97.6M Q4 '13: -89M Q1 '14: -85.8M Q2 '14: -88.4M Q3 '14: -85.5M Q4 '14: -90.9M Q1 '15: -86.8M Q2 '15: -75.3M Q3 '15: -61M Q4 '15: -51.5M Q1 '16: -50.7M Q2 '16: -50.4M Q3 '16: -66.3M Q4 '16: -69.2M Q1 '17: -67.1M Q2 '17: -72.7M Q3 '17: -67.7M Q4 '17: -78M Q1 '18: -87.1M Q2 '18: -93.5M Q3 '18: -99.6M Q4 '18: -70.5M Q1 '19: -63.7M Q2 '19: -58.7M Q3 '19: -46.5M Q4 '19: -66.9M Q1 '20: -28.1M Q2 '20: -25M Q3 '20: -27.7M Q4 '20: -29.7M Q1 '21: -11.5M Q2 '21: -7.7M Q3 '21: -14.5M Q4 '21: -17.9M Q1 '22: -84.9M Q2 '22: -84.5M Q3 '22: -82.6M Q4 '22: -58.6M Q1 '23: -44.7M Q2 '23: -37.8M Q3 '23: -24.4M Q4 '23: -25.1M Q1 '24: -19.8M Q2 '24: -14.2M Q3 '24: 3.9M Q4 '24: 17.5M Q1 '25: 37.2M Q2 '25: 97.8M Q3 '25: 113.3M Q4 '25: 367M Q1 '26: 364.2M Q2 '26: 321.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 9M 18M 27M Q1 '19: 394K Q2 '19: 675K Q3 '19: 916K Q4 '19: 906K Q1 '20: 954K Q2 '20: 922K Q3 '20: 752K Q4 '20: 895K Q1 '21: 1.1M Q2 '21: 906K Q3 '21: 917K Q4 '21: 1.1M Q1 '22: 888K Q2 '22: 1.8M Q3 '22: 1.9M Q4 '22: 1.7M Q1 '23: 2.6M Q2 '23: 2.6M Q3 '23: 3.7M Q4 '23: 7.1M Q1 '24: 8.2M Q2 '24: 9.9M Q3 '24: 16.6M Q4 '24: 18.6M Q1 '25: 21M Q2 '25: 22.7M Q3 '25: 19.5M Q4 '25: 19.6M Q1 '26: 19.8M Q2 '26: 23.8M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '11: -40.5M Q4 '11: -69.4M Q1 '12: -71.9M Q2 '12: -75.5M Q3 '12: -82.3M Q4 '12: -85.2M Q1 '13: -87M Q2 '13: -87.6M Q3 '13: -88.7M Q4 '13: -86.1M Q1 '14: -77.4M Q2 '14: -76M Q3 '14: -73.7M Q4 '14: -69.8M Q1 '15: -35.3M Q2 '15: -33.5M Q3 '15: -24.6M Q4 '15: -23.4M Q1 '16: -63.8M Q2 '16: -64.1M Q3 '16: -77.2M Q4 '16: -75.9M Q1 '17: -74.2M Q2 '17: -75.3M Q3 '17: -70.3M Q4 '17: -77.6M Q1 '18: -80.2M Q2 '18: -87.7M Q3 '18: -90.2M Q4 '18: -58.8M Q1 '19: -36M Q2 '19: -25.7M Q3 '19: -20.2M Q4 '19: -41.5M Q1 '20: -44M Q2 '20: -41.4M Q3 '20: -46.3M Q4 '20: -52.2M Q1 '21: -69M Q2 '21: 207K Q3 '21: 9.4M Q4 '21: 5.9M Q1 '22: 196K Q2 '22: -67.9M Q3 '22: -70.9M Q4 '22: -73.8M Q1 '23: -52.2M Q2 '23: -33.4M Q3 '23: -21.4M Q4 '23: -5.7M Q1 '24: -6.7M Q2 '24: -12.3M Q3 '24: 10.7M Q4 '24: 31.5M Q1 '25: 35.6M Q2 '25: 65.8M Q3 '25: 68.2M Q4 '25: 75.7M Q1 '26: 79.3M Q2 '26: 79.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '11: -43.5M Q4 '11: -71.7M Q1 '12: -74.9M Q2 '12: -78.6M Q3 '12: -85.3M Q4 '12: -88.6M Q1 '13: -89.5M Q2 '13: -89.5M Q3 '13: -90.4M Q4 '13: -87.3M Q1 '14: -78.1M Q2 '14: -76.6M Q3 '14: -74M Q4 '14: -70.2M Q1 '15: -35.6M Q2 '15: -33.8M Q3 '15: -25.2M Q4 '15: -24M Q1 '16: -64.7M Q2 '16: -65.1M Q3 '16: -78.2M Q4 '16: -76.7M Q1 '17: -74.8M Q2 '17: -75.6M Q3 '17: -70.4M Q4 '17: -77.7M Q1 '18: -80.5M Q2 '18: -88.7M Q3 '18: -91.3M Q4 '18: -59.9M Q1 '19: -37.3M Q2 '19: -26.4M Q3 '19: -21.1M Q4 '19: -43M Q1 '20: -45.7M Q2 '20: -42.9M Q3 '20: -47.6M Q4 '20: -53.4M Q1 '21: -69.8M Q2 '21: -970K Q3 '21: 8.2M Q4 '21: 5.3M Q1 '22: -584K Q2 '22: -68.3M Q3 '22: -71.3M Q4 '22: -74.2M Q2 '12 Q4 '13 Q2 '15 Q4 '16 Q2 '18 Q4 '19 Q2 '21 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '10: 52.5M Q3 '10: 52.8M Q1 '11: 52.3M Q2 '11: 58.3M Q3 '11: 71.2M Q1 '12: 71.4M Q2 '12: 71.5M Q3 '12: 71.6M Q1 '17: 113.6M Q2 '17: 122.5M Q3 '17: 124.6M Q4 '17: 144.3M Q1 '18: 147.1M Q2 '18: 161.6M Q3 '18: 166.5M Q4 '18: 167.6M Q1 '19: 167.2M Q2 '19: 167.2M Q3 '19: 167.6M Q4 '19: 168.5M Q1 '20: 168.6M Q2 '20: 168.6M Q3 '20: 168.9M Q4 '20: 169M Q1 '21: 176.1M Q2 '21: 170.2M Q3 '21: 170.9M Q1 '22: 171.8M Q2 '22: 172.1M Q3 '22: 172.8M Q1 '23: 173.6M Q2 '23: 17.4M Q3 '23: 17.4M Q1 '24: 17.5M Q2 '24: 17.5M Q3 '24: 17.6M Q1 '25: 18.2M Q2 '25: 18.2M Q3 '25: 19.2M Q1 '26: 19.7M Q2 '26: 19.6M Q3 '11 Q3 '17 Q1 '19 Q3 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.00 0.00 7.00 14.00 21.00 Q4 '11: -1.39 Q1 '12: -1.31 Q2 '12: -1.29 Q3 '12: -1.40 Q4 '12: -1.32 Q1 '13: -1.29 Q2 '13: -1.20 Q3 '13: -1.11 Q4 '13: -1.01 Q1 '14: -0.97 Q2 '14: -1.00 Q3 '14: -0.97 Q4 '14: -1.03 Q1 '15: -0.99 Q2 '15: -0.86 Q3 '15: -0.70 Q4 '15: -0.59 Q1 '16: -0.57 Q2 '16: -0.56 Q3 '16: -0.72 Q4 '16: -0.74 Q1 '17: -0.68 Q2 '17: -0.69 Q3 '17: -0.59 Q4 '17: -0.61 Q1 '18: -0.65 Q2 '18: -0.65 Q3 '18: -0.65 Q4 '18: -0.45 Q1 '19: -0.39 Q2 '19: -0.35 Q3 '19: -0.28 Q4 '19: -0.40 Q1 '20: -0.16 Q2 '20: -0.14 Q3 '20: -0.15 Q4 '20: -0.17 Q1 '21: -0.08 Q2 '21: -0.06 Q3 '21: -0.10 Q4 '21: -0.11 Q1 '22: -0.49 Q2 '22: -0.49 Q3 '22: -0.48 Q4 '22: -3.44 Q1 '23: -3.36 Q2 '23: -3.66 Q3 '23: -3.88 Q4 '23: -0.74 Q1 '24: -1.13 Q2 '24: -0.81 Q3 '24: 0.22 Q4 '24: 0.98 Q1 '25: 2.08 Q2 '25: 5.42 Q3 '25: 6.18 Q4 '25: 19.47 Q1 '26: 19.28 Q2 '26: 16.88 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.